[CROSS SYNC] ≪First in Japan≫ “CROSS SYNC,” a medical start-up certified venture from Yokohama City University, is a Class II Obtained medical device certification for medical device program “Biological Monitoring Application iBSEN DX” and started sales and introduction
*View in browser* *CROSS SYNC*
Press release: May 8, 2024
**
≪First in Japan≫ “CROSS SYNC,” a medical start-up certified venture from Yokohama City University, is a Class II medical device program “Biological monitoring application
Obtained medical device certification for “iBSEN DX” and started sales and introduction.
*Japan Society of Intensive Care Medicine “Remote ICU”
Launched as a patient monitoring application that complies with “Guidelines for Installation and Operation.” At Yokosuka City Municipal Hospital, iBSEN
Build a remote ICU system using DX. *
Biological monitoring application iBSEN DX
CROSS SYNC Co., Ltd. (Headquarters: Kanazawa-ku, Yokohama,
Representative Directors: Shunsuke Takagi and Akira Nakanishi, hereinafter referred to as the “Company”) announced on March 8, 2024 that it will launch the “Biological Monitoring Application”
iBSEN DX” has been certified as a medical device *1. In addition, the Japanese Society of Intensive Care Medicine has established “Remote ICU
We began selling this as Japan’s first*2 patient monitoring
application that complies with the “Guidelines for Installation and Operation,” and delivered it to Yokohama City University Hospital. In addition, at Yokosuka City Municipal Hospital, iBSEN
Using DX, we built a remote ICU system with Yokohama City University Hospital and started a demonstration test.
*1 “Biological monitoring application iBSEN
The research and development of “DX” was adopted in 2021 by the Japan Agency for Medical Research and Development (AMED) Medical-Engineering Collaboration/Artificial Intelligence Implementation Research Project, “AI technology using multimodal medical data including live images of patients. We are receiving support for the implementation research of a D-to-D remote ICU telemedicine service equipped with an AI monitoring function that automates the physical observation findings and severity assessment of critically ill patients.
*2 For applications that have obtained medical device certification that contributes to remote ICU. (As of April 2024, according to our research)
[About iBSEN DX]
“iBSEN DX”
DX) is an application that centrally manages the information necessary to understand the condition of patients hospitalized in critical care beds, and also enables monitoring at a location away from the critical care beds. EWS (Early
Warning Score*3) and S.I. (Shock
Calculate the index*4). Each calculated score and its change amount is graphed, and a unique score of CSS (Change Severity) is created. By displaying information such as the patient’s score and patient images together, changes in the patient’s condition can be monitored and indicators to support patient care can be provided.
*3 Early Warning Score: A general term for scores that predict the risk of sudden changes based on vital signs. There are NEWS, MEWS, etc.
*4 Shock index: An index used for initial evaluation of hemorrhagic shock. Can be measured using heart rate and systolic blood pressure values.
Exhibited at the 51st Academic Meeting of the Japanese Society of Intensive Care Medicine
・Introduction record: Yokohama City University Hospital
From April 2024, Yokohama City University Hospital will use the iBSEN patient monitoring application.
We have started using DX to monitor patients in the HCU (High Care Unit), which has been added to a different floor from the ICU (Intensive Care Unit). Biological monitoring application iBSEN By using DX, it is possible to prevent unexpected sudden changes in patients from being overlooked, improve the immediacy of patient information transmission between medical professionals, realize ICU-level care even in remote locations, and provide predictable patient care. Reduce harm. It is also expected to reduce the complexity of patient management tasks and contribute to work style reform by improving work efficiency.
[Programmed medical equipment]
Medical device classification: Controlled medical device, class II Product sales name: Biological monitoring application iBSEN DX Manufacturing and sales certification acquisition date: March 8, 2024 Certification number: No. 306AFBZX00012000
[Usage in remote ICU]
・Yokosuka City Municipal Hospital
Yokosuka City Municipal Hospital will launch the iBSEN patient monitoring application in April 2024 with support from the AMED Medical-Engineering Collaboration/Artificial Intelligence
Implementation Research Project.
Using DX, we built a remote ICU system with Yokohama City University Hospital and started a remote ICU demonstration test. Patient monitoring application iBSEN
By building a remote ICU monitoring system using DX, we will be able to receive accurate remote support from experienced intensive care physicians and nurses, helping to improve the quality of medical care. At our company, we will utilize the remote ICU know-how that we have developed in collaboration with Yokohama City University to develop iBSEN
We will roll out a remote ICU system that incorporates DX nationwide. Remote ICU image
[About CROSS SYNC Co., Ltd.]
Our company eliminates the concept of an intensive care unit and provides an ICU-like medical environment for every hospital bed. Our vision is to provide patients and medical facilities with a better future than the present by maximizing the potential of medical care through the use of technology and medical big data. We are taking on the challenge of changing the current situation.
URL: https://cross-sync.co.jp/
【Company Profile】
Company name: CROSS SYNC Co., Ltd.
Head office location: 236-0004
Room A507, Clinical Research Building, Fukuura Campus, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa Prefecture Contact: https://cross-sync.co.jp/contactus/
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000009.000075703.html
*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=75703&release_id=9
Unsubscribe HTML email
Copyright © PR TIMES Corporation All Rights Reserved.